Dual GLP-1/GIP receptor agonists, such as tirzepatide, combine the benefits of GLP-1 with those of glucose-dependent insulinotropic peptide (GIP). By targeting both GLP-1 and GIP pathways, these dual agonists provide enhanced effects on glucose regulation, appetite suppression, and fat metabolism, promising even greater glycemic control and weight management than GLP-1 alone. Such dual-action therapies have additional benefits in cardiovascular and anti-inflammatory health, expanding the therapeutic applications of GLP-1 to include comprehensive metabolic and cardiovascular benefits, making it a valuable agent in managing complex metabolic disorders.
Mehdi, S.F., Pusapati, S., Anwar, M.S., Lohana, D., Kumar, P., Nandula, S.A., Nawaz, F.K., Tracey, K., Yang, H., LeRoith, D., Brownstein, M.J. and Roth, J., 2023. Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent. Frontiers in Immunology
Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.
For detailed information about Semaglutide by Xeno Labs, consult with your doctor or healthcare professional.
Mehdi, S.F., Pusapati, S., Anwar, M.S., Lohana, D., Kumar, P., Nandula, S.A., Nawaz, F.K., Tracey, K., Yang, H., LeRoith, D., Brownstein, M.J. and Roth, J., 2023. Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent. Frontiers in Immunology
Mehdi, S.F., Pusapati, S., Anwar, M.S., Lohana, D., Kumar, P., Nandula, S.A., Nawaz, F.K., Tracey, K., Yang, H., LeRoith, D., Brownstein, M.J. and Roth, J., 2023. Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent. Frontiers in Immunology
Mehdi, S.F., Pusapati, S., Anwar, M.S., Lohana, D., Kumar, P., Nandula, S.A., Nawaz, F.K., Tracey, K., Yang, H., LeRoith, D., Brownstein, M.J. and Roth, J., 2023. Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent. Frontiers in Immunology
Home
